Filters








1 Hit in 0.096 sec

Plasma 8-hydroxy-2′-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10

K.M. Biglan, E.R. Dorsey, R.V.V. Evans, C.A. Ross, S. Hersch, I. Shoulson, W. Matson, K. Kieburtz, for the Huntington Study Group Pre2CARE Investigators
2012 Journal of Huntington's Disease  
We analyzed plasma 8OHdG concentrations in 20 individuals enrolled in the Pre-2CARE study before and after treatment with CoQ. Treatment resulted in a mean reduction in 8OHdG of 2.9 ± 2.9 pg/ml for the cohort (p = 0.0003) and 3.0 ± 2.6 pg/ml, for the HD group (p = 0.002). Baseline 8OHdG levels were not different between individuals with HD and controls (19.3 ± 3.2 pg/ml vs. 19.5 ± 4.7 pg/ml, p = 0.87) though baseline CoQ levels were elevated in HD compared with controls (p < 0.001). CoQ
more » ... 0.001). CoQ treatment reduces plasma 8OHdG and this reduction may serve as a marker of pharmacologic activity of CoQ in HD.
doi:10.3233/jhd-2012-120007 fatcat:ne6qjfltr5eyfftoase4sof5ji